StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) stock

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.85+0.04 (+5.13%)

Close on Nov 18, 2026Market cap $109.78MP/E –Yield –

Organogenesis operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Organogenesis's operating cash flow for the twelve months ending Jun 30, 2026 was $31.97M. For fiscal 2025 it was -$10.31M, down 172.6% from the year before. The highest annual figure on record is $61.98M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.31M-172.6%
FY2024Dec 31, 2024$14.21M-54.0%
FY2023Dec 31, 2023$30.92M+24.4%
FY2022Dec 31, 2022$24.86M-59.9%
FY2021Dec 31, 2021$61.98M+1033.9%
FY2020Dec 31, 2020$5.47M–
FY2019Dec 31, 2019-$33.53M–
FY2018Dec 31, 2018-$60.64M–
FY2017Dec 31, 2017-$3.49M–
FY2016Dec 31, 2016-$4.87M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.65M–
Q1 FY2026Mar 31, 2026$21.13M–
Q4 FY2025Dec 31, 2025$39.42M+260.4%
Q3 FY2025Sep 30, 2025$3.08M-64.6%
Q2 FY2025Jun 30, 2025-$32.87M-793.8%
Q1 FY2025Mar 31, 2025-$19.94M–
Q4 FY2024Dec 31, 2024$10.94M+3.0%
Q3 FY2024Sep 30, 2024$8.70M-48.0%
Q2 FY2024Jun 30, 2024$4.74M-45.2%
Q1 FY2024Mar 31, 2024-$10.16M–
Q4 FY2023Dec 31, 2023$10.61M+36.1%
Q3 FY2023Sep 30, 2023$16.73M+206.9%
Q2 FY2023Jun 30, 2023$8.65M-15.2%
Q1 FY2023Mar 31, 2023-$5.08M-459.8%
Q4 FY2022Dec 31, 2022$7.80M-56.5%
Q3 FY2022Sep 30, 2022$5.45M-80.4%
Q2 FY2022Jun 30, 2022$10.20M-41.7%
Q1 FY2022Mar 31, 2022$1.41M–
Q4 FY2021Dec 31, 2021$17.95M-22.7%
Q3 FY2021Sep 30, 2021$27.85M+214.0%
Q2 FY2021Jun 30, 2021$17.48M–
Q1 FY2021Mar 31, 2021-$1.30M–
Q4 FY2020Dec 31, 2020$23.22M–
Q3 FY2020Sep 30, 2020$8.87M–
Q2 FY2020Jun 30, 2020-$9.34M–
Q1 FY2020Mar 31, 2020-$17.28M–
Q4 FY2019Dec 31, 2019-$6.40M–
Q3 FY2019Sep 30, 2019-$5.45M–
Q2 FY2019Jun 30, 2019-$12.12M–
Q1 FY2019Mar 31, 2019-$9.56M–
Q4 FY2018Dec 31, 2018-$17.41M–
Q3 FY2018Sep 30, 2018-$22.99M–
Q2 FY2018Jun 30, 2018-$15.78M–
Q1 FY2018Mar 31, 2018-$4.46M–
Q4 FY2017Dec 31, 2017-$3.00M–
Q3 FY2017Sep 30, 2017-$168.73K–
Q2 FY2017Jun 30, 2017-$199.74K–
Q1 FY2017Mar 31, 2017-$126.29K–
Q4 FY2016Dec 31, 2016-$4.85M–

More Organogenesis figures

See a number that looks wrong?